Bayer’s Stock Hinges on a Supreme Court Coin Toss as a Major Backer Quietly Exits

Bayer secures regulatory wins in Europe and US, but Temasek reduces stake; investors await Supreme Court glyphosate ruling with 60% chance of victory.

Bayer’s shareholders are being pulled in opposite directions. The company notched a fresh regulatory win in the US and secured a long-sought easing of European gene-editing rules, yet one of its most prominent investors quietly trimmed its exposure. The net effect: all eyes remain fixed on a single courtroom in Washington.

Singapore’s sovereign wealth fund Temasek reduced its stake in Bayer to 2.90% on 8 June, down from 4.17% and below the threshold that triggers public disclosure. The filing gave no reason for the partial retreat, only noting that Temasek acts independently of political considerations. The move effectively removes one of the group’s most visible institutional backers from the public radar, leaving the market to guess at any further adjustments.

Against that backdrop, the stock has been jittery. Shares briefly jumped nearly 4% midweek to €37.29, nudging above the 200-day moving average, before slipping back to trade around €36.08 – bang on that same average. Year to date the stock remains about 5% in the red.

Fresh Tailwinds from Two Continents

The midweek surge was fuelled by a double dose of good news. In Europe, the European Parliament voted overwhelmingly to relax the rules on new genomic techniques, meaning many crop varieties will no longer require lengthy approval processes. Bayer, which has ploughed heavily into innovative seeds, stands to bring its research to European fields much faster.

Across the Atlantic, the US Food and Drug Administration approved Ambelvist, a magnetic resonance imaging contrast agent that uses roughly 60% less gadolinium than existing products. The green light opens the world’s largest healthcare market for the drug, which had already been cleared in Japan.

On the pharma pipeline front, the European Medicines Agency has accepted Bayer’s marketing application for asundexian, a stroke treatment. Improving margins in the pharmaceuticals division are helping to cushion the impact of patent expiries on other key drugs. The pressure to rein in debt now falls on Judith Hartmann, who took over as chief financial officer in early June.

The Binary Bet That Overpowers Everything

Yet none of these operational advances have shifted investors’ focus away from the calendar. The US Supreme Court is expected to rule on the “Durnell” glyphosate case by the end of June, or early July at the latest. The question before the justices is whether federal approval of the herbicide pre-empts state-level lawsuits – a ruling that could wipe out roughly 80% of the outstanding claims against Bayer.

Analysts at Berenberg and UBS assign roughly a 60% probability that Bayer prevails, making the outcome almost a coin flip. Berenberg nudged its price target up to €40.50 but warns that a defeat could drive the stock down to €30. UBS remains far more bullish, reiterating a buy rating with a €52 target.

For now, the share price is caught in a holding pattern. The market is effectively pricing in the risk of a loss while leaving room for a sharp re-rating if the ruling goes the company’s way. Until then, every piece of positive operational news – from gene-edited crops to a new contrast agent – provides only temporary support. The real catalyst is the one no one can predict.